Meeting
2020 ASCO Virtual Scientific Program
Differential effects of epirubicin and docetaxel on the immune system in patients with breast cancer (BC).
Authors
Kerstin Wimmer
Department of Surgery and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria
Kerstin Wimmer , Monika Sachet , Hanna Birnleitner , Ruth Exner , Martin Filipits , Michael Gnant , Florian Fitzal , Rudolf Oehler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 588)
DOI
10.1200/JCO.2020.38.15_suppl.588
Abstract #
588
Poster Bd #
80
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Moderate physical exercise and immune system modulation in patients with breast cancer treated with neoadjuvant chemotherapy.
First Author: Ornella Garrone
Poster
2016 ASCO Annual Meeting
The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel—Health-related quality of life during ongoing therapy.
First Author: Yvonne Brandberg
First Author: Begoña Bermejo
Poster
2013 ASCO Annual Meeting
A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.
First Author: Takashi Ishikawa